FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG
Links:
FDA Approves Abatacept for Pediatric Patients With Psoriatic Arthritis
https://wb.md/3MpQ2pK
01-11-2023